Interview with Joe Moore, Founder & CEO of Psychedelics Today

Compass Pathways (CMPS:NASDAQ) published amazing COMP360 Psilocybin Study results that will serve as support for companies working with psilocybin and psilocybin derivatives. However, this isn’t the only news worth mentioning.
Field Trip Health (FTRP: CSE) and (FTRPF: OTC) recently uplisted on the TSX ( Toronto Stock Exchange) and has filed an application to uplist on the Nasdaq.
While this is great news for Field Trip, it is not the only company who has filed to uplist. Silo Pharma, (SILO: OTC), has also put in an application to list on NASDAQ.
MagicMed will also join the ranks, however it will be through an acquisition.

Moreover, Cybin (CYBN: NEO,) and (CLXPF: OTC), is working on a transportable, wearable, helmet that completes a brain scan, through a partnership with a company called Kernel.
There is also news on Mydecine ( MYCO: NEO) and ( MYCOF: OTC) and MindCure (CSE: MCUR) (OTCQB: MCURF), so stay tuned till the end!

Enjoy the episode!

Timestamps:

0:00 – Intro
0:51 – Compass Pathways COMP360 Study Results
3:37 – Cybin Ketamine Study
7:14- Field Trip Uplists on the TSX And Applies To List On The NASDAQ
11:10 – Silo Pharma Applies To Uplist on The NASDAQ
12:11 – MagicMed to List On NASDAQ Through Acquisition
15:16- Mydecine Expands Cultivation Capabilities for Psilocybin
17:32- MINDCURE Completes First Stage of Manufacturing Synthetic Ibogaine

Links:
Compass Pathways Study Results On The Safety And Cognitive Effects Of Taking a Dose Of Psilocybin COMP360:
https://www.globenewswire.com/news-release/2021/06/03/2241445/0/en/COMPASS-Pathways-and-Kings-College-London-publish-cognition-results-from-COMP360-psilocybin-study-in-healthy-volunteers.html

Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics
https://psilocybinalpha.com/news/cybin-announces-sponsorship-of-a-kernel-flow-feasibility-study-to-measure-ketamines-psychedelic-effects-on-cerebral-cortex-hemodynamics

Field Trip Health Uplists on the TSX:
https://www.globenewswire.com/news-release/2021/06/03/2241200/0/en/Field-Trip-Health-Ltd-to-Commence-Trading-on-the-Toronto-Stock-Exchange-on-June-7-2021.html

FTRP Applies To Uplist On NASDAQ:
https://stockhouse.com/news/the-market-herald-news/2021/06/08/field-trip-health-tsx-ftrp-applies-to-list-on-nasdaq-stock-market

MagicMed Will Be Acquired by Nasdaq-listed Enveric Biosciences
https://psilocybinalpha.com/news/magicmed-to-be-acquired-by-nasdaq-listed-company

Health Canada Has Approved an Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms MYCO: NEO), (MYCOF: OTC) :
https://finance.yahoo.com/news/health-canada-approves-expansion-mydecine-113000924.html

MINDCURE, (CSE: MCUR) (OTCQB: MCURF), Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research:
https://www.prnewswire.com/news-releases/mindcure-successfully-completes-first-stage-of-manufacturing-synthetic-ibogaine-for-use-in-psychedelic-clinical-research-301304810.html

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
editing:@themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#CompassPathways #Mydecine #FieldTrip

BIG news for Mydecine (MYCO : NEO) (MYCOF: OTC) and Numinus Wellness (NUMI: NEO)
(LKYSF : OTC). But The BIGGER NEWS is that we are finally launching our website: https://thepsychedelicinvestor.com/, where we will be sharing the latest industry news for all of your favorite companies.
We hope we can facilitate our community’s path to information about the psychedelic sector. We would like to invite you to share your opinions and suggestions down in the comment section.

Last but not least, if you wish to collaborate and become a contributor for The Psychedelic Investor, you’re welcome to send us an email at thepsychedelicinvestor@gmail.com or fill in a form on our website! We welcome your opinion and you can have a shot at seeing your name in the opinion section of our website!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Links:

Numinus Wellness (TSXV: NUMI, OTC: LKYSF), Filed a Patent Application for their Proprietary Rapid Production Process of Psilocybe Mushrooms and Other Psychoactive Fungi Species:
https://thepsychedelicinvestor.com/2021/06/24/numinus-files-u-s-provisional-patent-application-for-a-proprietary-rapid-production-process-for-psilocybe-and-other-psychoactive-fungi-species/

Mydecine (NEO: MYCO, OTC: MYCOF), Will Attempt To Treat Substance Use Disorder and Nicotine Addiction With Their MYCO-004 Molecule:
https://thepsychedelicinvestor.com/2021/06/24/mydecine-selects-substance-use-disorder-and-smoking-cessation-for-novel-psychedelic-molecule-myco-004/

Mydecine’s 4 Proprietary Compounds Advancing To Clinical Trials: Myco 001, 002, 003, 004:
https://thepsychedelicinvestor.com/2021/04/07/mydecine-announces-four-lead-novel-drug-candidates-and-prepares-for-pre-ind-meetings-with-the-fda-and-health-canada-to-prepare-for-human-clinical/

Johns Hopkins psilocybin study results:
https://www.hopkinsmedicine.org/news/stories/mushrooms_quit_smoking.html

Roth Capital Initiates Coverage On Mydecine Innovations with Buy Rating, Announces Price Target of 3$:
https://www.benzinga.com/news/21/06/21664391/roth-capital-initiates-coverage-on-mydecine-innovations-with-buy-rating-announces-price-target-of-c

Enjoy the episode!

Timestamps:
0:00 – Intro
1:37- Numinus’ patent application to speed up their psilobe mushrooms’ production process
4:53 – Mydecine announces it will use their MYCO – 004 molecule to treat substance use disorder and addiction
9:15 – Roth Capital says that Mydecine is a BUY with a price target of $3

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Numinus #Mydecine #NUMIStock

Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
We are going to do this because one, it’s a good article that I wanted to share with you
And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.

P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.html

Time Stamps
0:00​ – Intro
3:10 – Media Coverage on Tesla & Psychedelic Stocks
6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
8:05 – Influence on stock valuations and stealth investors
10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To Grow

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor

Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​ ​ #MindmedStock​​ #PsychedelicStocks